39.11
39.11 (0%)
As of Feb 14, 2025
Supernus Pharmaceuticals Inc. [SUPN]
Source:
Company Overview
Supernus Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
| Country | United States |
| Headquarters | rockville, maryland |
| Phone Number | (301) 838-2500 |
| Industry | manufacturing |
| CEO | Jack A. Khattar |
| Website | www.supernus.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $661.8 |
| Operating Profit | $81.7 |
| Net Income | $73.9 |
| Net Cash | $-5.7 |
Profit Ratios
| Gross Margin | $583.9 |
| Operating Margin | 12.3 |
| Profit as % of Revenues | 790.5% |
| Profit as % of Assets | 5.6% |
| Profit as % of Stockholder Equity | 7.1% |
Management Effectiveness
| Return on Equity | 7.1% |
| Return on Assets | 5.4% |
| Turnover Ratio | 50% |
| EBITA | $159.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,368.1 |
| Total Liabilities | $332.3 |
| Operating Cash Flow | $172 |
| Investing Cash Flow | $-189.9 |
| Financing Cash Flow | $12.2 |
